Search
Halozyme Therapeutics Inc
HALOAdd to Watchlist
72.635USD
+1.485+2.09%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
8.56BMarket Cap
24.57P/E TTM
More Details of Halozyme Therapeutics Inc Company
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme Therapeutics Inc Info
Ticker SymbolHALO
Company nameHalozyme Therapeutics Inc
IPO dateJan 30, 2003
CEOTorley (Helen I)
Number of employees350
Security typeOrdinary Share
Fiscal year-endJan 30
Address12390 El Camino Real
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18587948889
Websitehttps://www.halozyme.com/
Ticker SymbolHALO
IPO dateJan 30, 2003
CEOTorley (Helen I)
Company Executives of Halozyme Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
767.78K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
77.83K
+4.88%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
38.49K
--
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.05K
-103.63%
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Ms. Barbara Duncan
Ms. Barbara Duncan
Independent Director
Independent Director
--
--
Ms. Tram Bui
Ms. Tram Bui
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
767.78K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
77.83K
+4.88%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
38.49K
--
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.05K
-103.63%
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Halozyme Therapeutics Inc?
The top five shareholders of Halozyme Therapeutics Inc are: Dr. Helen I. Torley
How many institutions hold shares of Halozyme Therapeutics Inc (HALO)?
As of 2026Q1, 1232 institutions hold shares of Halozyme Therapeutics Inc, with a combined market value of approximately 138.78M, accounting for 117.14% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5105303.00.
What is the biggest source of revenue for Halozyme Therapeutics Inc?
In 2026Q1, the Royalties business generated the highest revenue for Halozyme Therapeutics Inc, amounting to 867.84M and accounting for 62.14% of total revenue.
